AMP-activated protein kinase : implications on ischemic diseases
Ischemia is a blockage of blood supply due to an embolism or a hemorrhage in a blood vessel. When an organ cannot receive oxygenated blood and can therefore no longer replenish its blood supply due to ischemia, stresses, such as the disruption of blood glucose homeostasis, hypoglycemia and hypoxia, activate the AMPK complex. LKB1 and CaMKKβ are essential activators of the AMPK signaling pathway. AMPK triggers proangiogenic effects through the eNOS protein in tissues with ischemic conditions, where cells are vulnerable to apoptosis, autophagy and necrosis. The AMPK complex acts to restore blood glucose levels and ATP levels back to homeostasis. This review will discuss AMPK, as well as its key activators (LKB1 and CaMKKβ), as a central energy regulator and evaluate the upstream and downstream regulating pathways of AMPK. We will also discuss how we can control this important enzyme in ischemic conditions to prevent harmful effects in patients with vascular damage.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
BMB reports - 45(2012), 9 vom: 15. Sept., Seite 489-95 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ahn, Yong-Joo [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 11.02.2013 Date Revised 03.12.2021 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM221320121 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM221320121 | ||
| 003 | DE-627 | ||
| 005 | 20231224051553.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2012 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0737.xml |
| 035 | |a (DE-627)NLM221320121 | ||
| 035 | |a (NLM)23010169 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ahn, Yong-Joo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a AMP-activated protein kinase |b implications on ischemic diseases |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.02.2013 | ||
| 500 | |a Date Revised 03.12.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Ischemia is a blockage of blood supply due to an embolism or a hemorrhage in a blood vessel. When an organ cannot receive oxygenated blood and can therefore no longer replenish its blood supply due to ischemia, stresses, such as the disruption of blood glucose homeostasis, hypoglycemia and hypoxia, activate the AMPK complex. LKB1 and CaMKKβ are essential activators of the AMPK signaling pathway. AMPK triggers proangiogenic effects through the eNOS protein in tissues with ischemic conditions, where cells are vulnerable to apoptosis, autophagy and necrosis. The AMPK complex acts to restore blood glucose levels and ATP levels back to homeostasis. This review will discuss AMPK, as well as its key activators (LKB1 and CaMKKβ), as a central energy regulator and evaluate the upstream and downstream regulating pathways of AMPK. We will also discuss how we can control this important enzyme in ischemic conditions to prevent harmful effects in patients with vascular damage | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Multienzyme Complexes |2 NLM | |
| 650 | 7 | |a Nitric Oxide Synthase Type III |2 NLM | |
| 650 | 7 | |a EC 1.14.13.39 |2 NLM | |
| 650 | 7 | |a Protein Serine-Threonine Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a STK11 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a Calcium-Calmodulin-Dependent Protein Kinase Kinase |2 NLM | |
| 650 | 7 | |a EC 2.7.11.17 |2 NLM | |
| 650 | 7 | |a AMP-Activated Protein Kinase Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.3 |2 NLM | |
| 650 | 7 | |a AMP-Activated Protein Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.31 |2 NLM | |
| 650 | 7 | |a Glucose |2 NLM | |
| 650 | 7 | |a IY9XDZ35W2 |2 NLM | |
| 700 | 1 | |a Kim, Hwewon |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, Heejin |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Max |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Yuhyun |e verfasserin |4 aut | |
| 700 | 1 | |a Moon, Sangjun |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Hyeon Soo |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Hyung-Hwan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMB reports |d 2008 |g 45(2012), 9 vom: 15. Sept., Seite 489-95 |w (DE-627)NLM177900369 |x 1976-670X |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2012 |g number:9 |g day:15 |g month:09 |g pages:489-95 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2012 |e 9 |b 15 |c 09 |h 489-95 | ||